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Abstract
Background: Delirium is characterized by acute changes in mental status including inattention, disorganized thinking,
and altered level of consciousness, and is highly prevalent in critically ill adults. Delirium has adverse consequences for
both patients and the healthcare system; however, at this time, no effective treatment exists. The identification of
effective prevention strategies is therefore a clinical and research imperative. An important limitation of previous
reviews of delirium prevention is that interventions were considered in isolation and only direct evidence was
used. Our systematic review will synthesize all existing data using network meta-analysis, a powerful statistical
approach that enables synthesis of both direct and indirect evidence.
Methods: We will search Ovid MEDLINE, CINAHL, Embase, PsycINFO, and Web of Science from 1980 to March 2016.
We will search the PROSPERO registry for protocols and the Cochrane Library for published systematic reviews. We will
examine reference lists of pertinent reviews and search grey literature and the International Clinical Trials Registry
Platform for unpublished studies and ongoing trials. We will include randomized and quasi-randomized trials of
critically ill adults evaluating any pharmacological, non-pharmacological, or multi-component intervention for
delirium prevention, administered in or prior to (i.e., peri-operatively) transfer to the ICU. Two authors will independently
screen search results and extract data from eligible studies. Risk of bias assessments will be completed on all included
studies. To inform our network meta-analysis, we will first conduct conventional pair-wise meta-analyses for primary and
secondary outcomes using random-effects models. We will generate our network meta-analysis using a Bayesian
framework, assuming a common heterogeneity parameter across all comparisons, and accounting for correlations
in multi-arm studies. We will perform analyses using WinBUGS software.
(Continued on next page)
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Discussion: This systematic review will address the existing knowledge gap regarding best practices for delirium
prevention in critically ill adults by synthesizing evidence from trials of pharmacological, non-pharmacological,
and multi-component interventions administered in or prior to transfer to the ICU. Use of network meta-analysis
will clarify which delirium prevention strategies are most effective in improving clinical outcomes while causing
least harm. The network meta-analysis is a novel approach and will provide knowledge users and decision makers
with comparisons of multiple interventions of delirium prevention strategies.
Systematic review registration: PROSPERO CRD42016036313
Keywords: Delirium, Prevention, Intensive care unit, Network meta-analysis
Abbreviations: ICU, Intensive care unit; NMA, Network meta-analysis; PRISMA, Preferred Reporting Items for
Systematic Reviews and Meta-Analyses
Background
Delirium is a syndrome commonly experienced by pa-
tients in the intensive care unit (ICU), and is character-
ized by acute changes in mental status including
inattention, disorganized thinking, and altered level of
consciousness [1]. Reported delirium prevalence rates
range from 60 to 89 % in mechanically ventilated, and
40 to 60 % in non-ventilated, critically ill patients [2, 3].
Numerous studies have explored risk factors associated
with the development of delirium in critically ill popula-
tions, with varying results. In a recent systematic review
of 33 studies, significant risk factors included increased
age, dementia, hypertension, ICU admission due to
emergency surgery or trauma, higher illness severity [4],
mechanical ventilation, metabolic acidosis, history of de-
lirium, and coma [5]. Delirium in critically ill patients
has been associated with multiple adverse patient conse-
quences such as prolonged duration of mechanical ven-
tilation and length of ICU and hospital stay, as well as
increased mortality and greater likelihood of long-term
cognitive impairment, functional decline, and placement
in long-term care facilities [6–13].
At this time, there are no effective treatments for ICU
delirium; [14, 15] it is therefore imperative to explore
potential prevention strategies. Such strategies fall
broadly into pharmacological, non-pharmacological, and
multi-component interventions, and can be adminis-
tered once in the ICU or prior to (e.g., peri-operative)
admission. Pharmacological interventions include anti-
psychotics (e.g., haloperidol), sedatives (e.g., benzodiaze-
pines, propofol), alpha-agonists (e.g., dexmedetomidine,
clonidine), cholinesterase inhibitors (e.g., rivastigmine),
melatonin and melatonin receptor agonists, HMG-CoA
reductase inhibitors (statins), and anesthetics. Non-
pharmacological strategies include interventions to pro-
mote sleep (e.g., noise and light reduction), relaxation
(e.g., touch, music), movement (e.g., early mobilization),
and patient orientation [14, 16]. Non-pharmacological
strategies may be evaluated singularly, but are more
often employed as multi-component approaches de-
signed to address delirium risk factors such as cognitive
impairment, sleep deprivation, immobility, visual and
hearing impairment, and dehydration.
The Society of Critical Care Medicine’s 2013 Pain,
Agitation, and Delirium (PAD) guidelines state that
there is no compelling evidence to make specific rec-
ommendations for any pharmacological intervention to
reduce delirium incidence [14]. A recent (2015) system-
atic review [17] of pharmacological strategies for the
prevention and treatment of ICU delirium, however, re-
ported that while pharmacological interventions were
not associated with a significant reduction in delirium
prevalence or duration of mechanical ventilation, these
did show a possible favorable effect on length of ICU stay.
As it pertains to trials evaluating non-pharmacological or
multi-component interventions, these have shown positive
results in hospitalized, non-critically ill patients [18, 19],
and numerous trials are underway in critically ill popula-
tions and will be available for consideration in the near fu-
ture. The Society of Critical Care Medicine’s 2013 PAD
guidelines recommend the non-pharmacological strategy
of early mobilization whenever possible to reduce the inci-
dence and duration of delirium.
An important limitation of previous systematic reviews
on delirium prevention is that interventions were con-
sidered in isolation and only direct evidence from head-
to-head comparisons was used. Our systematic review
will synthesize existing data from identified trials using
network meta-analysis (NMA), a powerful statistical ap-
proach that enables synthesis of both direct and indir-
ect evidence in a multi-treatment analytical framework
[20–22]. This approach will allow the assessment of the
relative efficacy and safety of interventions that may or
may not have been directly compared in randomized
controlled trials. We will also expand the scope of
considered interventions to include anesthetic drug ma-
nipulations made prior to transfer to the ICU (e.g.,
intra-operatively) and sedation administration strategies
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(e.g., daily sedation interruption or protocolized sed-
ation) employed in the ICU.
The primary objective of this systematic review is to
compare interventions for delirium prevention (pharma-
cological and non-pharmacological) in critically ill adults
using NMA, thus informing clinicians and other know-
ledge users of the safest and most effective strategies.
The assessment of the comparative benefits and harms
of each intervention via NMA will permit the ranking
of interventions according to their effectiveness and
acceptability, therefore informing policy and clinical
decision-making.
Methods
This systematic review protocol was prepared using the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocol (PRISMA-P) guidelines [23]. A
PRISMA-P checklist was completed (Additional file 1).
The protocol for this review has been registered on the
PROSPERO International Prospective Register of Sys-
tematic Reviews (CRD42016036313).
Data sources and search strategy
We created a preliminary search strategy (Additional file 2)
with the assistance of an experienced senior information
specialist. A second senior information specialist reviewed
the search strategy prior to its execution using the
Peer Review for Electronic Search Strategies (PRESS)
template [24, 25]. We will search the following electronic
databases from 1980 to March 2016: Ovid MEDLINE,
Ovid MEDLINE In-Process & Other Non-Indexed Cita-
tions, CINAHL, Embase Classic + Embase, PsycINFO,
and Web of Science. Search terms will include extensive
controlled vocabulary and keywords such as “intensive
care unit” and “delirium.” We will use a validated random-
ized controlled trial filter and perform a separate search
for published systematic reviews in the Cochrane Library
and in PROSPERO. We will review reference lists of rele-
vant trials and reviews for additional studies not identified
through our electronic search methods. We will per-
form a grey literature search using sources listed in
the Canadian Agency for Drugs and Technologies in
Health’s (CADTH) Grey Matters [26]. We will search
for unpublished studies and ongoing trials on the
International Clinical Trials Registry Platform (http://
apps.who.int/trialsearch).
Study eligibility criteria
We will include randomized controlled trials, including
those using open-label and quasi-randomized (i.e.,
quasi-random method of allocation such as alternation)
designs. We will include studies that evaluate any inter-
vention designed to prevent delirium in critically ill
adults. We will exclude studies with non-randomized de-
signs (e.g., cohort studies, case reports, case series).
Population
Our population of interest is critically ill adults aged
16 years and older, and treated in an ICU or critical care
unit of any type (e.g., medical, surgical, trauma, mixed,
burn, cardiac, or cardiac surgery) or in a high-acuity
unit. For trials enrolling both ICU and non-ICU pa-
tients, we will include the following: trials where a mini-
mum of 50 % of subjects are ICU patients, or those
where fewer than 50 % of subjects are ICU patients but
that report outcome data for the ICU group distinct
from that of the total study population. We will also in-
clude trials where an intervention is applied outside of
the ICU (e.g., in the operating room), so long as the pa-
tient population is expected to be transferred to the ICU
(e.g., cardiac surgery). Trials including patients con-
firmed as delirious at enrolment will be excluded. How-
ever, we will include trials where some or all patients are
deemed to have sub-syndromal delirium [27, 28].
Interventions
We will include trials that evaluate any intervention
designed to prevent delirium in critically ill adults, or
that evaluate interventions not specifically targeted to
delirium prevention but necessarily include incidence
as an a priori-defined outcome that is measured
across treatment groups (e.g., sedation administration
strategies). Interventions may comprise, but are not
limited to, any pharmacological (e.g., typical and atyp-
ical antipsychotics, benzodiazepines, alpha-2 agonists,
opioids, cholinesterase inhibitors, melatonin, melatonin
receptor agonists, propofol), non-pharmacological (e.g.,
noise reduction, early mobilization, music therapy, acu-
puncture), or multi-component strategy. Additionally, we
will include trials that evaluate sedative drugs (e.g., propo-
fol versus midazolam) and/or sedation administration
strategies (e.g., protocolized sedation, daily sedation inter-
ruption, intermittent dosing, continuous dosing, opioid
only sedation) that report delirium incidence as a primary
or secondary outcome. Such studies will be included be-
cause sedative exposure has been identified as a poten-
tially modifiable risk factor for delirium [5, 14, 29–32].
Additionally, sedation administration strategies in critic-
ally ill patients generally aim to achieve sufficient wakeful-
ness, enabling patients to be assessed for delirium and
participate in reorientation and early mobilization strat-
egies [29]. Lastly, we will include studies in which pre-
and intra-operative interventions are applied in patients
admitted post-operatively to the ICU (e.g., cardiac surgery)
that report delirium incidence as a primary or secondary
outcome. Such studies can include those in which
interventions for delirium prevention are investigated
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specifically (e.g., dexmedetomidine), or those in which
routinely applied drugs (e.g., analgesic and anesthetic
agents) and/or intra-operative techniques (e.g., depth of
anesthesia) are compared.
Comparators
An NMA is capable of estimating comparisons of
multiple interventions based on both direct and indir-
ect evidence [20–22]. Using this unique approach, we
will include all trials evaluating any of the aforemen-
tioned strategies, regardless of the intervention used
in the control arm (i.e., whether the study compares
one delirium prevention strategy to another, placebo,
or care as usual (Fig. 1)). Descriptions of care as
usual will be extracted verbatim from studies to en-
sure that similarities and differences are appropriately
reflected in the NMA.
Outcomes
Our primary outcome of interest is delirium incidence,
defined as at least one episode of delirium experienced
during ICU admission and identified using either a vali-
dated delirium screening tool (e.g., Confusion Assess-
ment Method (CAM-ICU) [33], Intensive Care Delirium
Screening Checklist (ICDSC) [34], or the Neelon and
Champagne (NEECHAM) Confusion Scale [35]), the
assessment of a trained individual (e.g., psychiatrist)
using Diagnostic and Statistical Manual of Mental
Disorders IV or V criteria [1, 36], or as otherwise de-
fined by study authors.
Secondary outcomes include the following: number of
delirium- and coma-free days, total duration of delirium,
delirium severity, incidence of sub-syndromal delirium
(for those without sub-syndromal detected on enrol-
ment) [27, 28], defined as the presence of sub-threshold
delirium symptoms that do not progress to delirium,
duration of mechanical ventilation, duration of ICU and
hospital length of stay, mortality, adverse events (e.g.,
QT interval prolongation, seizures), use of physical re-
straints, disposition at hospital discharge, and long-term
cognitive and health-related quality of life outcomes
after hospital discharge. As mortality may be defined at
various time points, we will extract all reported mortality
outcomes and create subgroups where needed for de-
scriptive and analytical purposes.
Screening and data extraction
Two authors (LB, MG) will independently screen search
results against eligibility criteria to identify potentially
relevant studies. We will perform a calibration exercise
prior to screening to ensure inter-rater reliability by pilot
testing the predesigned screening form on a sample of
five studies. References will be organized using the refer-
ence management software package EndNote (X7 edi-
tion, Thomson Reuters, available at http://endnote.com/).
The full text version of published manuscripts, or ab-
stracts, in the case of unpublished or ongoing studies,
identified by either author, will be examined independ-
ently to confirm inclusion; reasons for exclusion will be
Protocolized 
sedation
Continuous 
dosing
Intermittent 
dosing
No-sedation/ 
analgesia onlyDaily 
Interruption
Placebo
Music 
therapy
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antipsychotics
Atypical 
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Fig. 1 Interventions eligible for network meta-analysis. Lines reflect where comparisons may exist between treatments. Which comparisons have
been studied will be established by studies identified. Availability of outcomes can also impact network structure. Clinical experts have guided
the network refinement
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listed in the notes field of EndNote. Any disagreement
will be discussed with an independent arbiter (LR).
We will present a summary of the search and study
selection process using a PRISMA flow diagram [37].
As we anticipate a large number of eligible trials, we
will divide studies among pairs of authors (DW/SM, IE/
SK, and NA/MG). Each member of an author pair will
independently extract data using a standardized elec-
tronic data extraction form using Microsoft Excel ver-
sion 14.6.2 (Microsoft Corporation, Seattle, WA, USA).
We have piloted the extraction form on five studies to
ensure it captures all relevant data. We will extract data
on participant demographics (e.g., age, gender, severity
of illness score, reasons for ICU admission), verbatim
descriptions of delirium prevention and comparator arm
interventions, methods of delirium assessment, use of
sedation and pain scales, and any co-interventions that
may influence the development of delirium such as
avoidance of medications that may be associated with
delirium (e.g., benzodiazepines), as well as data on our
selected outcomes of interest.
We will contact study corresponding authors as neces-
sary to clarify issues related to data reporting, risk of bias,
or to obtain further study details. All data extraction will
be confirmed (LB, MG) and, where necessary, any discrep-
ancy will be resolved by an independent arbiter (LR).
Study risk of bias assessment
Each data extractor will independently assess risk of bias
of their assigned studies, and a third author (LR) will
confirm the final bias assessment. We will use a domain-
based evaluation for risk of bias assessment, as recom-
mended by the Cochrane Collaboration [38]. The do-
mains are as follows: (1) random sequence generation
(i.e., selection bias); (2) allocation concealment (i.e., se-
lection bias); (3) blinding of participants and personnel
(i.e., performance bias); (4) blinding of outcomes assess-
ment (i.e., detection bias); (5) incomplete outcome data
(i.e., attrition bias); (6) selective reporting; and (7) other
bias (e.g., source of funding). For hard endpoints such as
mortality, incidence of delirium, and duration of mech-
anical ventilation, a lack of blinding does not immedi-
ately warrant a judgment of high risk of bias as this
aspect of study design is not considered to have a biasing
effect on the endpoints. Each endpoint and the risk of bias
will be assessed individually to generate an overall score.
For each domain, we will assess the risk of bias as “low,”
“high,” or “unclear.” Unclear risk will be assigned for a
domain if insufficient detail is reported and cannot be ob-
tained from study authors, or if what happened in the
study is known, but its contribution to the risk of bias is
unknown or unclear. After risk of bias assessment , stud-
ies will be classified according to the following categories:
1. Low risk: studies where all domains are considered
to be at “low” risk of bias;
2. High risk: studies where one or more domains are
considered to be at “high” risk of bias; and
3. Unclear risk: studies where one or more domain(s)
have “unclear” risk of bias.
Approach to evidence synthesis
In the NMA each intervention will have its own node
(Fig. 1). If we encounter combined interventions of both
pharmacological and non-pharmacological strategies, the
research team will be consulted to determine the best
approach for analysis.
To inform the NMA, we will first conduct conven-
tional pair-wise meta-analyses for the primary and all
secondary outcomes using random-effects models, pro-
vided at least two studies reporting a given outcome are
available [39]. Pair-wise meta-analyses will be generated
for each comparison of unique interventions within the
final treatment network.
The research team will collectively review and discuss
extracted characteristics of included studies to assess the
extent of clinical and methodological diversity. We will
summarize characteristics of included studies focusing
on clinical (e.g., type of delirium prevention strategy)
and methodological (e.g., risk of bias) homogeneity. We
will review the distribution of these potential effect mod-
ifiers across studies in the network to determine the val-
idity of the assumptions of homogeneity and similarity.
These analyses, along with corresponding inspections of
I2 values and distributions of treatment effects, will
permit judgments about whether sufficient homogeneity
exists within comparisons in the treatment network. If
homogeneity is established, we will progress to perform-
ing the planned NMA.
We will generate the NMA using a Bayesian frame-
work, assuming a common heterogeneity parameter
across all comparisons and accounting for correlations
in multi-arm studies [40, 41]. We will perform analyses
using WinBUGS software [42] (version 1.4.3, MRC
Biostatistics Unit, Cambridge, UK) (http://www.mrc-
bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/)
through well-established methods.
We will express continuous and binary outcomes in
terms of mean differences and odds ratios, respectively,
with corresponding 95 % confidence intervals [43–45].
Secondary summary measures including treatment rank-
ings and Surface Under the Cumulative Ranking
(SUCRA) curve will also be provided [41]. We will
evaluate adequacy of model fit through comparison of
the posterior residual deviance with the number of un-
constrained data points (i.e., the total number of inter-
ventions across studies) [45]. Adequate fit is deemed
present when these quantities are approximately equal.
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Both fixed- and random-effects consistency models will
be run, and their fit will be compared using the Devi-
ance Information Criterion, which penalizes model fit
for complexity (lower values indicate better models)
[46]. A difference of approximately five points or more
will be considered indicative of an important difference.
Inconsistency models will also be fitted, and we will
compare their Deviance Information Criterion values
with those of consistency models to explore the presence
of inconsistency. If inconsistency is detected, individual
study characteristics will be examined, as will the need
for additional statistical considerations such as meta-
regression. We will assess model convergence using
established methods including Gelman Rubin diagnos-
tics and inspection of Monte Carlo errors [45].
Subgroup and sensitivity analyses
We will explore subgroup analyses and/or meta-
regression analyses to address the impact of covariates
on our findings to establish their robustness. If we
identify sufficient data, we will seek to determine if
the efficacy and safety of prevention strategies are in-
fluenced by (1) age (<65, ≥65 years) and (2) ICU
population (e.g., mixed, medical only, surgical only).
We will conduct a sensitivity analysis excluding studies
at high risk of bias. Additionally, we will conduct a sen-
sitivity analysis involving alternative geometries of the
network. Examples of potential reformulation of the net-
work include (1) collapsing atypical and typical antipsy-
chotics into one node and (2) splitting each node in
Fig. 1 into two to reflect “low” and “high” drug doses.
Reporting of review findings
We will adhere to recommendations from the PRISMA-
NMA extension statement on NMA for reporting our
review findings [47]. We will include recommended
graphical approaches such as forest plots, league tables,
and rank-o-grams [41]. We will provide a summary of
the geometries of the networks to provide insight for fu-
ture clinical trials.
Dissemination of findings
We have chosen to use the knowledge-to-action frame-
work [48–50], which emphasizes the successful imple-
mentation of research evidence into practice in two
phases: (1) knowledge creation and (2) action. We will
solicit input from knowledge users and key stakeholder
in order to generate project recommendations and
knowledge translation opportunities. We will formally
communicate our findings via summary documents,
with versions tailored to specific audiences (e.g., patients
and family members, clinicians, researchers, policy
makers), presentations delivered at local, national, and
international forums, and publications in peer-reviewed
journals. We will hold an end-of-study workshop where
key stakeholders will discuss findings, provide feedback
on summary documents, and strategize further know-
ledge dissemination strategies. We will distribute sum-
maries to various relevant advocacy programs.
Discussion
This systematic review will address the existing know-
ledge gap regarding best practice for delirium preven-
tion in critically ill adults. An NMA approach to
evidence synthesis will be used to evaluate trials
employing pharmacological, non-pharmacological, and
multi-component interventions for delirium preven-
tion, enabling the identification of strategies that most
improve clinical outcomes while causing least harm.
Use of NMA to evaluate delirium prevention inter-
ventions is novel and will provide knowledge users
and decision-makers with comparisons of multiple
interventions.
The NMA is an important but as of yet under-utilized
method of evaluating interventions for the prevention of
delirium in critically ill patients. In a field where a sub-
stantial body of evidence exists, clinicians may be unable
to establish which approach is most effective because
only traditional pair-wise comparisons are available to
support guideline development and inform clinical prac-
tice. Given that multiple types of delirium prevention in-
terventions are currently in use, we believe a new
systematic review that employs a more sophisticated ap-
proach to evidence synthesis is warranted. The use of
NMA will provide clinicians and researchers with clarity
regarding the relative effectiveness and safety of available
options, as well as enabling the identification of patients
most likely to benefit. Further, we will provide re-
searchers with a solid framework of current knowledge
and identify evidence gaps to guide future research.
Registration
This systematic review is registered with PROSPERO, an
international prospective register of systematic reviews
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42016036313).
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Additional file 1: Preferred Reporting Items for Systematic Review and
Meta-Analyses Protocol (PRISMA-P). PRISMA-P items and their respective
line locations within the manuscript. (DOCX 135 kb)
Additional file 2: Preliminary search strategy. Preliminary search
strategy, including all queried databases, search parameters, and key
words. (DOCX 112 kb)
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